Abivax (CHIX:ABVXP) Total Equity : €196.01 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Abivax Total Equity?

Abivax's total equity for the quarter that ended in Dec. 2023 was €196.01 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Abivax Total Equity Historical Data

The historical data trend for Abivax's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Total Equity Chart

Abivax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

Get a 7-Day Free Trial

18.59

17.90

25.93

7.19

196.01

Abivax Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Equity	Get a 7-Day Free Trial															25.93	6.08	7.19	80.49	196.01

Abivax Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Abivax's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	327.062	-	131.052
	=	196.01

Abivax's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	327.062	-	131.052
	=	196.01

Abivax Total Equity Related Terms

Thank you for viewing the detailed overview of Abivax's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax (CHIX:ABVXP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (CHIX:ABVXp) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA ABVX:France 2X10:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based biotechnology company. It is focused on using antiviral technology platforms targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein in the nucleus or the cytoplasm of the infected cell during viral infection, the Immune stimulation platform focuses on invariant natural killer agonists and the Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma.

Abivax (CHIX:ABVXP) Headlines

No Headlines